Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?

Germaine Hanquet; Anne Perrocheau; Esther Kissling; Daniel Levy Bruhl; David Tarragó; James Stuart; Pawel Stefanoff; Sigrid Heuberger; Paula Kriz; Anne Vergison; Sabine C de Greeff; Andrew Amato-Gauci; Lucia Pastore Celentano; ECDC Country Experts for Pneumococcal Disease; Zitta Barrella Harboe

doi:10.1016/j.vaccine.2010.03.069

Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?

Germaine Hanquet, Anne Perrocheau, Esther Kissling, Daniel Levy Bruhl, David Tarragó, James Stuart, Pawel Stefanoff, Sigrid Heuberger, Paula Kriz, Anne Vergison, Sabine C de Greeff, Andrew Amato-Gauci, Lucia Pastore Celentano, ECDC Country Experts for Pneumococcal Disease, Zitta Barrella Harboe (Medlem af forfattergruppering)

Abstract

In this era of new pneumococcal conjugate vaccines (PCV), we described and compared surveillance of invasive pneumococcal disease (IPD) and PCV policies in 30 European countries to provide guidance for Europe-wide surveillance. We confirmed the heterogeneity of surveillance systems and case definitions across countries but identified elements common to all countries, such as the availability of serotyping and the surveillance of pneumococcal meningitis. PCV impact was monitored in 11/15 countries using it. We propose steps for the monitoring of incidence rates and serotype distribution at EU level, to assess the need to introduce PCV and monitor its impact once introduced.

Originalsprog	Engelsk
Tidsskrift	Vaccine
Vol/bind	28
Udgave nummer	23
Sider (fra-til)	3920-8
Antal sider	9
ISSN	0264-410X
DOI	https://doi.org/10.1016/j.vaccine.2010.03.069
Status	Udgivet - 21 maj 2010
Udgivet eksternt	Ja

Adgang til dokumentet

10.1016/j.vaccine.2010.03.069

Citationsformater

Hanquet, G., Perrocheau, A., Kissling, E., Bruhl, D. L., Tarragó, D., Stuart, J., Stefanoff, P., Heuberger, S., Kriz, P., Vergison, A., de Greeff, S. C., Amato-Gauci, A., Celentano, L. P., ECDC Country Experts for Pneumococcal Disease, & Harboe, Z. B. (2010). Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system? Vaccine, 28(23), 3920-8. https://doi.org/10.1016/j.vaccine.2010.03.069

Hanquet, G, Perrocheau, A, Kissling, E, Bruhl, DL, Tarragó, D, Stuart, J, Stefanoff, P, Heuberger, S, Kriz, P, Vergison, A, de Greeff, SC, Amato-Gauci, A, Celentano, LP, ECDC Country Experts for Pneumococcal Disease & Harboe, ZB 2010, 'Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?', Vaccine, bind 28, nr. 23, s. 3920-8. https://doi.org/10.1016/j.vaccine.2010.03.069

@article{570e47ce56b14440a9f544879da9e667,

title = "Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?",

abstract = "In this era of new pneumococcal conjugate vaccines (PCV), we described and compared surveillance of invasive pneumococcal disease (IPD) and PCV policies in 30 European countries to provide guidance for Europe-wide surveillance. We confirmed the heterogeneity of surveillance systems and case definitions across countries but identified elements common to all countries, such as the availability of serotyping and the surveillance of pneumococcal meningitis. PCV impact was monitored in 11/15 countries using it. We propose steps for the monitoring of incidence rates and serotype distribution at EU level, to assess the need to introduce PCV and monitor its impact once introduced.",

keywords = "Disease Notification, Europe/epidemiology, Humans, Immunization Programs, Incidence, Meningitis, Pneumococcal/epidemiology, Pneumococcal Infections/epidemiology, Pneumococcal Vaccines/administration & dosage, Population Surveillance/methods, Serotyping, Vaccines, Conjugate/administration & dosage",

author = "Germaine Hanquet and Anne Perrocheau and Esther Kissling and Bruhl, {Daniel Levy} and David Tarrag{\'o} and James Stuart and Pawel Stefanoff and Sigrid Heuberger and Paula Kriz and Anne Vergison and {de Greeff}, {Sabine C} and Andrew Amato-Gauci and Celentano, {Lucia Pastore} and {ECDC Country Experts for Pneumococcal Disease} and Harboe, {Zitta Barrella}",

year = "2010",

month = may,

day = "21",

doi = "10.1016/j.vaccine.2010.03.069",

language = "English",

volume = "28",

pages = "3920--8",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "23",

}

TY - JOUR

T1 - Surveillance of invasive pneumococcal disease in 30 EU countries

T2 - Towards a European system?

AU - Hanquet, Germaine

AU - Perrocheau, Anne

AU - Kissling, Esther

AU - Bruhl, Daniel Levy

AU - Tarragó, David

AU - Stuart, James

AU - Stefanoff, Pawel

AU - Heuberger, Sigrid

AU - Kriz, Paula

AU - Vergison, Anne

AU - de Greeff, Sabine C

AU - Amato-Gauci, Andrew

AU - Celentano, Lucia Pastore

AU - ECDC Country Experts for Pneumococcal Disease

A2 - Harboe, Zitta Barrella

PY - 2010/5/21

Y1 - 2010/5/21

N2 - In this era of new pneumococcal conjugate vaccines (PCV), we described and compared surveillance of invasive pneumococcal disease (IPD) and PCV policies in 30 European countries to provide guidance for Europe-wide surveillance. We confirmed the heterogeneity of surveillance systems and case definitions across countries but identified elements common to all countries, such as the availability of serotyping and the surveillance of pneumococcal meningitis. PCV impact was monitored in 11/15 countries using it. We propose steps for the monitoring of incidence rates and serotype distribution at EU level, to assess the need to introduce PCV and monitor its impact once introduced.

AB - In this era of new pneumococcal conjugate vaccines (PCV), we described and compared surveillance of invasive pneumococcal disease (IPD) and PCV policies in 30 European countries to provide guidance for Europe-wide surveillance. We confirmed the heterogeneity of surveillance systems and case definitions across countries but identified elements common to all countries, such as the availability of serotyping and the surveillance of pneumococcal meningitis. PCV impact was monitored in 11/15 countries using it. We propose steps for the monitoring of incidence rates and serotype distribution at EU level, to assess the need to introduce PCV and monitor its impact once introduced.

KW - Disease Notification

KW - Europe/epidemiology

KW - Humans

KW - Immunization Programs

KW - Incidence

KW - Meningitis, Pneumococcal/epidemiology

KW - Pneumococcal Infections/epidemiology

KW - Pneumococcal Vaccines/administration & dosage

KW - Population Surveillance/methods

KW - Serotyping

KW - Vaccines, Conjugate/administration & dosage

U2 - 10.1016/j.vaccine.2010.03.069

DO - 10.1016/j.vaccine.2010.03.069

M3 - Journal article

C2 - 20394721

SN - 0264-410X

VL - 28

SP - 3920

EP - 3928

JO - Vaccine

JF - Vaccine

IS - 23

ER -

Surveillance of invasive pneumococcal disease in 30 EU countries: Towards a European system?

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater